+

WO2013083813A3 - Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis - Google Patents

Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis Download PDF

Info

Publication number
WO2013083813A3
WO2013083813A3 PCT/EP2012/074862 EP2012074862W WO2013083813A3 WO 2013083813 A3 WO2013083813 A3 WO 2013083813A3 EP 2012074862 W EP2012074862 W EP 2012074862W WO 2013083813 A3 WO2013083813 A3 WO 2013083813A3
Authority
WO
WIPO (PCT)
Prior art keywords
ssat
prevention
treatment
rheumatoid arthritis
spermine
Prior art date
Application number
PCT/EP2012/074862
Other languages
French (fr)
Other versions
WO2013083813A2 (en
Inventor
Michel Neidhart
Steffen Gay
Emmanuel KAROUZAKIS
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of WO2013083813A2 publication Critical patent/WO2013083813A2/en
Publication of WO2013083813A3 publication Critical patent/WO2013083813A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to inhibitors of SSAT or AMD for the prevention or treatment of rheumatoid arthritis. 4-[(2E)-2-(4-carbamimidoylphenyl)iminohydrazino]-benzamidine (Diminazen) is preferred.
PCT/EP2012/074862 2011-12-07 2012-12-07 Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis WO2013083813A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11192406 2011-12-07
EP11192406.4 2011-12-07

Publications (2)

Publication Number Publication Date
WO2013083813A2 WO2013083813A2 (en) 2013-06-13
WO2013083813A3 true WO2013083813A3 (en) 2013-08-01

Family

ID=47520900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/074862 WO2013083813A2 (en) 2011-12-07 2012-12-07 Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis

Country Status (1)

Country Link
WO (1) WO2013083813A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633423B2 (en) 2014-06-13 2020-04-28 Affibody Ab IL-6-binding polypeptide complex
US10669314B2 (en) 2014-06-13 2020-06-02 Affibody Ab Polypeptide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472181A2 (en) * 1990-08-22 1992-02-26 Merrell Pharmaceuticals Inc. 5-Amine substituted adenosine analogs as immunosuppressants
US20080207764A1 (en) * 2001-02-08 2008-08-28 Rotta Research Laboratorium S.P.A. Novel Benzamidine Derivatives Having Anti-Inflammatory and Immunosuppressive Activity
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin
WO2011009039A2 (en) * 2009-07-16 2011-01-20 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472181A2 (en) * 1990-08-22 1992-02-26 Merrell Pharmaceuticals Inc. 5-Amine substituted adenosine analogs as immunosuppressants
US20080207764A1 (en) * 2001-02-08 2008-08-28 Rotta Research Laboratorium S.P.A. Novel Benzamidine Derivatives Having Anti-Inflammatory and Immunosuppressive Activity
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin
WO2011009039A2 (en) * 2009-07-16 2011-01-20 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CRUNDWELL E: "THE SEARCH FOR CHEMOTHERAPEUTIC AMIDINES. PART XII. NN'-DI(AMIDINOPHENYL)AMIDINES", JOURNAL OF THE CHEMICAL SOCIETY. ABSTRACTS,, 1 January 1956 (1956-01-01), pages 368 - 371, XP009063805, ISSN: 0590-9791 *
DELRIEU F ET AL: "[Preliminary study of L-methionine in the treatment of rheumatoid polyarthritis]", REVUE DU RHUMATISME ET DES MALADIES OSTÉO-ARTICULAIRES, EXPANSION SCIENTIFIQUE FRANCAISE, PARIS, FR, vol. 55, no. 2, 1 December 1988 (1988-12-01), pages 995 - 997, XP009158725, ISSN: 0035-2659 *
HORNUNG NETE ET AL: "Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement", JOURNAL OF RHEUMATOLOGY, vol. 31, no. 12, December 2004 (2004-12-01), pages 2374 - 2381, XP009167846, ISSN: 0315-162X *
NEUMANN E ET AL: "Rheumatoid arthritis progression mediated by activated synovial fibroblasts", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, GB, vol. 16, no. 10, 1 October 2010 (2010-10-01), pages 458 - 468, XP027391788, ISSN: 1471-4914, [retrieved on 20100824] *
SENOLT L ET AL: "Prospective new biological therapies for rheumatoid arthritis", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 2, 1 December 2009 (2009-12-01), pages 102 - 107, XP026721952, ISSN: 1568-9972, [retrieved on 20090326], DOI: 10.1016/J.AUTREV.2009.03.010 *
VREUGDENHIL G ET AL: "ANEMIA IN RHEUMATOID ARTHRITIS THE ROLE OF IRON VITAMIN B-12 AND FOLIC ACID DEFICIENCY AND ERYTHROPOIETIN RESPONSIVENESS", ANNALS OF THE RHEUMATIC DISEASES, vol. 49, no. 2, 1990, pages 93 - 98, XP007921640, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
WO2013083813A2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3509590A4 (en) N-acyl amino acid compounds and methods of use
HUE036561T2 (en) Preparations for the treatment of rheumatoid arthritis and the use of procedures
IN2014DN10670A (en)
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
HK1246674A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2606452A4 (en) Reducing the dimensionality of the joint inversion problem
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
WO2012068109A3 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
NZ718373A (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
IL230705A0 (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
BR112014009866A2 (en) antibody formulations and methods
IL223865B (en) Calcium salts of dihydroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
MX356813B (en) Hydantoin derivatives useful as kv3 inhibitors.
WO2014153495A3 (en) Novel stat3 inhibitors
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
WO2013083813A3 (en) Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis
JP2013535391A5 (en)
EP3449917A3 (en) Tapentadol for preventing chronification of pain
WO2011133893A3 (en) Cyanide antidotes
RS55061B1 (en) Novel amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome
EP3555071A4 (en) Heparanase inhibitors and use thereof
IL286709A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12812545

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12812545

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载